Although Ki-67, p-MEK1/2, and p-ERK1/2 protein levels in vemurafenib-only group decreased compared with the placebo group in A375 cancer tissues, it failed to block the activation of RAS-MAPK signaling in BRAF wild-type CDX tissues. This evidence concerns the gene MAP2K1 and cancer.